Context Therapeutics (NASDAQ:CNTX) Downgraded by Lifesci Capital to Hold

Lifesci Capital cut shares of Context Therapeutics (NASDAQ:CNTX) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports.

A number of other analysts have also weighed in on CNTX. Weiss Ratings lowered shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a report on Thursday. Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Finally, Maxim Group cut their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.17.

Context Therapeutics Trading Down 4.0%

CNTX stock opened at $0.48 on Thursday. The stock has a market capitalization of $44.47 million, a P/E ratio of -1.01 and a beta of 1.74. Context Therapeutics has a 12 month low of $0.48 and a 12 month high of $3.62. The firm has a 50-day moving average price of $0.86 and a 200-day moving average price of $1.91.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.06). As a group, equities analysts predict that Context Therapeutics will post -0.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several large investors have recently modified their holdings of CNTX. Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the third quarter valued at $100,000. Blue Owl Capital Holdings LP increased its holdings in Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares during the period. Renaissance Technologies LLC raised its position in Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares during the last quarter. Finally, State Street Corp raised its position in Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.